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Abstract Purpose: Basal-like breast cancer is associated with high grade, poor prognosis, and younger
patient age. Clinically, a triple-negative phenotype definition [estrogen receptor, progesterone
receptor, and human epidermal growth factor receptor (HER)-2, all negative] is commonly used
to identify such cases. EGFR and cytokeratin 5/6 are readily available positive markers of basal-
like breast cancer applicable to standard pathology specimens.This study directly compares the
prognostic significance between three- and five-biomarker surrogate panels to define intrinsic
breast cancer subtypes, using a large clinically annotated series of breast tumors.
Experimental Design: Four thousand forty-six invasive breast cancerswere assembled into tis-
suemicroarrays.Allhadstaging,pathology, treatment, andoutcomeinformation;medianfollow-up
was12.5 years.Cox regressionanalyses and likelihood ratio tests compared theprognostic signifi-
cance forbreast cancerdeath-specific survival (BCSS)of the twoimmunohistochemicalpanels.
Results:Among3,744interpretablecases,17%werebasalusingthetriple-negativedefinition(10-
year BCSS, 6 7%) and 9%were basal using the five-markermethod (10-year BCSS, 62%).Likeli-
hoodratio testsofmultivariableCoxmodels includingstandardclinicalvariables show that the five-
marker panel is significantly more prognostic than the three-marker panel.The poor prognosis of
triple-negative phenotype is conferred almost entirely by those tumors positive for basalmarkers.
Amongtriple-negativepatients treatedwithadjuvantanthracycline-basedchemotherapy, theaddi-
tionalpositivebasalmarkers identifiedacohortofpatientswithsignificantlyworseoutcome.
Conclusions:The expanded surrogate immunopanel of estrogen receptor, progesterone recep-
tor, human HER-2, EGFR, and cytokeratin 5/6 provides a more specific definition of basal-like
breast cancer that better predicts breast cancer survival.
Breast cancer is a heterogeneous disease, and by gene
expression profiling has been shown to be classifiable into five
major biologically distinct intrinsic subtypes: luminal A,
luminal B, human epidermal growth factor receptor-2 (HER2)
overexpressing, basal-like, and normal-like (1–3). These
molecular subtypes have prognostic and predictive value:
the HER2-overexpressing and basal-like breast cancers have
poor outcomes, and within the estrogen receptor (ER)–positive
subtypes the luminal B cohort has a significantly worse
prognosis than luminal A. Follow-up studies have shown these
subtypes to be conserved across diverse patient series and array
platforms (4, 5), and have shown that different gene
expression–based predictors are likely tracking a similar,
common set of biological subtypes, with significant agreement
in predicting patient outcome (6).
Among the five intrinsic subtypes, basal-like breast cancers
have drawn particular attention, because they express neither
ER, progesterone receptor (PR), nor HER2, and therefore
would not be expected to benefit from antiestrogen
hormonal therapies nor from trastuzumab (7). Cost and
complexity issues have to date rendered gene expression
profiling impractical as a routine hospital diagnostic tool.
However, there are immunohistochemistry surrogate panels
proposed that can potentially identify basal-like breast cancer,
including ER-PR-HER2–negative [the ‘‘triple-negative pheno-
type’’ (TNP); ref. 8], and negative hormone receptors and
HER2 but either epidermal growth factor receptor (EGFR) or
cytokeratin 5/6 (CK5/6) positive (the ‘‘five-marker method’’;
refs. 9, 10). The TNP is convenient because it applies
standard biomarkers already routinely ordered during the
clinical work-up of breast cancer biopsies; however, this
approach has never been formally validated by correlating to
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the gold standard gene expression profiling and relies entirely
on negative results to identify basal-like breast cancers, a
strategy that may have an elevated risk of false assignments
for technical reasons with consequent decreased specificity.
On the other hand, including EGFR and CK5/6 as positive
immunohistochemical markers has previously been shown to
accurately identify basal-like tumors from gene microarray
data with 100% specificity and 76% sensitivity (9).
Approximately 15% of breast cancers are basal-like and are
associated with poor relapse-free and overall survival (9–11). A
recent population-based study has shown that this subtype is
more prevalent in premenopausal African American women
(10), which may contribute to the poor outcomes seen among
these patients. Hereditary BRCA-1 breast tumors also resemble
sporadic basal-like tumors (3, 12). Basal-like breast cancers are
likely to be mitotically active high-grade invasive tumors and
Table 1. Summary of clinicopathologic characteristics of 4,046 patients with invasive breast tumors included
in this tissue microarray series
Characteristics No. patients (%)
Age at diagnosis, y
V40 380 (9.4)
40-49 767 (19)
50-65 1,435 (35.5)
>65 1,464 (36.2)
Menstrual status at referral
Premenopausal 1,188 (29.4)
Postmenopausal 2,761 (68.2)
Pregnant 2 (0.1)
Unknown 95 (2.3)
Histology
Ductal 3,661 (90.5)
Lobular 308 (7.6)
Other 77 (1.9)
Grade
1 (well differentiated) 211 (5.2)
2 (moderately well or partially differentiated) 1,582 (39.1)
3 (poorly differentiated) 2,069 (51.1)
Unknown 184 (4.5)
Tumor size, cm
V2 2,093 (51.7)
2-5 1,697 (41.9)
>5 219 (5.4)
Unknown 37 (0.9)
Lymphovascular invasion
Positive 1,750 (43.3)
Negative 2,120 (52.4)
Unknown 176 (4.3)
Percentage of positive/total number of examined axillary lymph nodes (%)
0 2,161 (53.4)
0-25 876 (21.7)
>25 825 (20.4)
Unknown 184 (4.5)
Local therapy
No breast surgery 60 (1.5)
Mastectomy + radiation therapy 631 (15.6)
Mastectomy alone 1,557 (38.5)
Lumpectomy alone 135 (3.3)
Lumpectomy + radiation therapy 1,663 (41.1)
Adjuvant systemic therapy (AST)
None 1,689 (41.7)
Tamoxifen only 1,305 (32.3)
Ovarian ablation or hormone therapy other than tamoxifen 7 (0.2)
Chemotherapy only, AC 148 (3.7)
Chemotherapy AC + tamoxifen 125 (3.1)
Chemotherapy only, CMF 429 (10.6)
Chemotherapy CMF + tamoxifen 39 (1)
Chemotherapy only, FAC 92 (2.3)
Chemotherapy FAC + tamoxifen 68 (1.7)
Chemotherapy only (other) 70 (1.7)
Chemotherapy (other) + tamoxifen 69 (1.7)
Ovarian ablation or hormone therapy + chemotherapy 5 (0.1)
Abbreviations: AC, doxorubicin and cyclophosphamide; CMF, cyclophosphamide, methotrexate, and fluorouracil; FAC, fluorouracil, doxorubicin,
and cyclophosphamide.
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are associated with younger patient age (13, 14). A readily
available prognostic immunohistochemical surrogate, easily
applied on formalin-fixed, paraffin-embedded biopsy tissues,
would identify a cohort of breast cancer patients who may
require more aggressive systemic therapy and who would be the
most appropriate subjects for clinical trials specifically targeting
the basal-like subtype.
This study aims to compare the prognostic value of two
proposed surrogate immunohistochemical panels used to
identity basal-like breast cancers: the TNP and the five-marker
Core Basal definitions. Using a regional series of >4,000
primary invasive breast cancers with fully annotated clinical
data, this report investigates the association of these two
immunohistochemical panels with patient outcome.
Materials andMethods
Patients and tissue microarrays. The study cohort consists of 4,046
female primary invasive tumors. All patients had been referred to the
British Columbia Cancer Agency between 1986 and 1992 and have
staging, pathology, treatment, and follow-up information. The median
follow-up time was 12.5 years. During the study era, f75% of breast
cancer patients in the province were referred; the nonreferred were
generally elderly or treated by mastectomy without indications for
adjuvant systemic therapy (15). In British Columbia, most patients
were treated according to provincial guidelines developed and
disseminated by the British Columbia Cancer Agency (15). These
guidelines were based on age, tumor size, lymphovascular invasion,
nodal status, and ER levels determined by dextran charcoal ligand–
binding assay (16). High risk was defined as node positive, or if node
negative, presence of lymphovascular invasion, or tumor >2 cm and ER
negative (<10 fmol/mg). Patients considered as clinical ‘‘low risk’’ at the
time of diagnosis during the study era were not given any adjuvant
systemic therapy. Table 1 summarizes the tumor characteristics and
treatment regimens of the breast cancer patients in this retrospective
study, most of which have been previously presented (17). The
Vancouver Hospital ER laboratory retained single archival blocks from
each patient. Slides from these blocks were stained with H&E and
reviewed by two pathologists to identify areas of invasive breast
carcinoma. Tissue microarrays were constructed as previously described
(17). A total of 17 tissue array blocks were built. This study was
approved by the Clinical Research Ethics Board of the University of
British Columbia and the British Columbia Cancer Agency.
Immunohistochemistry and fluorescent in situ hybridization. Immu-
munohistochemistry for ER, PR, HER2, EGFR, and CK5/6 was done on
each set of 17 formalin-fixed, paraffin-embedded tissue slides using the
standard streptavidin-biotin complex method with 3,3¶-diaminobenzi-
dine chromogen. ER (Clone SP1, LabVision) antibody was used at 1:250
dilution with a 8-min microwave antigen retrieval in a 10 mmol/L (pH
6.0) citrate buffer. Ready-to-use PR (Clone 1E2, Ventana) antibody was
used following the Ventana automated stainer standard CC1 protocol.
EGFR staining was done using the EGFR pharmDx kit (DAKO) with an
enzymatic antigen retrieval by proteinase K for 5 min. CK5/6 (Clone D5/
16B4, Zymed Laboratories) antibody was used following the Ventana
automated stainer mild CC1 protocol with 1:100 dilution. HER2 staining
was done using HER2 (Clone SP3, LabVision) antibody at 1:100 dilution
with heat-induced antigen retrieval using 0.05 mol/L Tris buffer (pH
10.0) heated to 95jC in a steamer for 30 min. For HER2 fluorescent
in situ hybridization assay, slides were hybridized with probes to LSI
Her-2/neu and CEP 17 with the PathVysion HER-2 DNA Probe Kit
(Abbott Molecular, Inc.) according to the manufacturer’s instructions,
with modifications to the pretreatment and hybridization as previously
described (18). Slides were counterstained with 4¶,6-diamidino-2-phenyl-
indole and visualized on a Zeiss Axioplan epifluorescent microscope.
Automated analysis of fluorescent in situ hybridization signals was done
using a Metafer automated image acquisition and analysis system
(Metasystems). The average copy number for each probe was determined
and the amplification ratio was calculated as a ratio between the average
copy per cell for HER2 and the average copy number for centromere 17.
Biomarker expression from immunohistochemical assays were scored by
two pathologists, blinded to the clinicopathologic characteristics and
outcome of the breast tumors, using previously established and published
criteria developed on other breast cancer cohorts. ER (17) and PR stains
were considered positive if immunostaining was seen in >1% of tumor
nuclei. EGFR and CK5/6 stains were considered positive if any (weak or
strong) cytoplasmic and/or membranous invasive carcinoma cell staining
was observed (9). For HER2 status, tumors were considered positive if
scored as 3+ according to HercepTest criteria, and fluorescent in situ
hybridization with amplification ratio z2.0 was used to segregate
immunohistochemically equivocal (2+) results (19). All the stained
tissue microarrays are digitally scanned and available for public access
(username, basal4000; password, corebasal).5
Definition of breast cancer biological subtypes by immunohistochemis-
try. The immunohistochemical surrogate (ER, PR, HER2, EGFR, and
CK5/6) defining breast cancer subtypes has been previously published
(9, 10). In this study, we use two classification schemes: the TNP and
the five-biomarker method. Basal-like breast cancer is defined
differently by the two schemes. Using the TNP method, basal-like is
negative for all routinely tested biomarkers: ER, PR, and HER2 (ER-PR-
HER2-), and this surrogate definition of basal-like is referred to as TNP
in this article. Using the five-biomarker method, TNP becomes divided
into two groups: (a) triple-negative cases (ER-PR-HER2-), which also
positively express either EGFR or CK5/6, cases that are referred to as
Core Basal in this article; and (b) five-marker negative phenotype
(5NP), which is triple negative and furthermore expresses neither EGFR
nor CK5/6. Thus, the 5NP cases represent those cases considered basal-
like by the TNP method but not by the Core Basal definition. Three
other biological subtype definitions are common to both schemes:
HER2+/ER-PR- subtype, luminal¶ (ER+ and/or PR+, and HER2-), and
luminal/HER2+ (ER+ and/or PR+, and HER2+; Supplementary Table
S1). Tumors expressing HER2 but negative for both ER and PR were
defined as HER2+/ER-PR-. Tumors expressing HER2 and one of the
luminal markers (ER or PR) were defined as luminal/HER2+. Luminal/
HER2+ is not synonymous with the luminal B expression profile
subtype because only 30% to 50% of luminal B tumors express HER2.
Luminal¶ includes all cases that expression profiling defines as luminal
A, as well as those remaining luminal B tumors that do not express
HER2. Biomarker information was considered uninterpretable in cases
where the tissue core was lost during sectioning or processing, or
contained <50 visible invasive breast carcinoma cells. Tumors missing
any of ER, PR, or HER2 data are categorized as unassigned. The two
classification schemes are described in Supplementary Table S1.
Statistical analysis. All statistical analyses were carried out using
SPSS 14.0 (SPSS, Inc.) and R 2.4.0.6 Differences between breast cancer
subtypes with regard to clinicopathologic characteristics were examined
using m2 tests. For survival analysis, breast cancer-specific survival
(BCSS) was of primary interest. Survival time was calculated as the date
of a woman’s diagnosis of breast cancer until her date of death. Survival
times were censored if the primary or underlying cause of death was not
breast cancer, or if the patient was still alive on June 30, 2004 (the date
when the outcome data were collected). Univariate survival curves were
generated by the Kaplan-Meier method (20) and differences in survival
among the breast cancer subtypes were assessed by the log-rank test
(21). For multivariate analysis, we built Cox regression models (22) to
estimate the adjusted hazard ratios of breast cancer subtypes with
standard clinicopathologic variables: age at diagnosis, histologic grade,
tumor size, lymphovascular invasion, and number of positive axillary
lymph nodes as a percentage of the total number examined (23). Only
5 http://www.gpecimage.ubc.ca
6 http://www.r-project.org
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cases with information for all the covariates were included in the
analysis. Smoothed plots of weighted Schoenfeld residuals were used to
test proportional hazard assumptions (24). Separate Cox regression
models were also built for the subsets of patients (a) receiving no
adjuvant systemic therapy, to compare the prognostic values of the two
basal-like subtype definitions for studying the natural history of breast
cancer, and (b) receiving adjuvant chemotherapy, to estimate the
additional prognostic value of EGFR and CK5/6 for defining the basal-
like subtype in this setting.
To test the statistical significance of the additional biomarkers (EGFR
and CK5/6) for defining the basal-like subtype, a likelihood ratio test
(25, 26) of the differences between the nested Cox regression models
was used. The null hypothesis was that the five-biomarker model did
not describe BCSS differently than the three-biomarker model.
Bootstrap resampling analyses (27) were carried out (10,000
iterations) to assess the adequacy of the Cox model hazard ratio
confidence intervals. In this study, bootstrapping involved randomly
sampling the data with replacement and repeating the Cox regression
analyses to assess the hazard ratios. We found the bootstrap confidence
intervals were in close agreement with the model-based estimates,
yielding no evidence that the model was overfitted to the data. The
purpose of this study was to validate findings from other studies and to
test a relatively small number of prespecified hypotheses; accordingly,
we did not perform multiple comparisons corrections. All tests were
two-sided and P values <0.05 were considered statistically significant.
The data were assembled to provide >80% power for testing
hypotheses regarding the biomarkers in all patients combined, as well
as for patient subgroups defined by the adjuvant therapies they received.
Supplementary data. Supplementary Tables S1 and S2 and Supple-
mentary Fig. S1A and S1B are available on our publication supple-
mental Web site.7
Results
In this series of 4,046 tumors, the percentage of positive
expression among interpretable cases is 69.5% (2,791 of 4,015)
for ER, 13.0% (504 of 3,865) for HER2, 51.2% (1,846 of 3,605)
for PR, 13.3% (462 of 3,478) for EGFR, and 8.4% (287 of
3,400) for CK5/6. A total of 3,744 tumors with enough infor-
mation for unambiguous immunohistochemical surrogate
classification were defined into breast cancer biological
subtypes according to the TNP and the Core Basal classification
schemes, respectively. There were no statistically significant
survival differences between the 302 unassigned tumors and
the 3,744 classifiable tumors (log-rank P = 0.179). Among the
cases with complete data for assignment by both schemes, 17%
(639 of 3,744) were defined as basal-like breast cancers by the
triple-negative definition, whereas 9.0% (336 of 3,744) were
basal-like by the Core Basal definition (with the other 303
classified as 5NP).
Clinicopathologic characteristics of breast cancer subty-
pes. The tumor characteristics of each breast cancer subtype
are summarized in Table 2. With either classification scheme,
the major breast cancer subtypes differ significantly by age,
grade, tumor size, lymphovascular invasion, and percentage of
positive over total dissected axillary lymph nodes. For both the
TNP and the Core Basal classification, basal-like breast cancer is
7 http://www.gpec.ubc.ca/index.php?content=papers/basal4000.php
Table 2. Clinicopathologic characteristics of the 4,046 breast cancer tumors
Characteristic Luminal¶ Luminal/HER2+ HER2+/ER-PR-
Total n = 2,625 Total n = 222 Total n = 258
Age, y n (% within subtype) n (% within subtype) n (% within subtype)
V40 184 (7.0) 21 (9.5) 37 (14.3)
40-49 476 (18.1) 49 (22.1) 45 (17.4)
50-65 921 (35.1) 78 (35.1) 112 (43.4)
>65 1,044 (39.8) 74 (33.3) 64 (24.8)
Grade n (% within subtype) n (% within subtype) n (% within subtype)
1 174 (6.6) 4 (1.8) 2 (0.8)
2 1,244 (47.4) 56 (25.2) 53 (20.5)
3 1,082 (41.2) 155 (69.8) 196 (76)
Unknown 125 (4.8) 7 (3.2) 7 (2.7)
Tumor size, cm n (% within subtype) n (% within subtype) n (% within subtype)
V2 1,455 (55.4) 90 (40.5) 105 (40.7)
2-5 1,041 (39.7) 118 (53.2) 127 (49.2)
>5 106 (4.0) 13 (5.9) 20 (7.8)
Unknown 23 (0.9) 1 (0.5) 6 (2.3)
LVI n (% within subtype) n (% within subtype) n (% within subtype)
Positive 1,100 (41.9) 133 (59.9) 137 (53.1)
Negative 1,406 (53.6) 84 (37.8) 113 (43.8)
Unknown 119 (4.5) 5 (2.3) 8 (3.1)
Percentage of
positive/total
examined axillary
lymph nodes (%)
n (% within subtype) n (% within subtype) n (% within subtype)
0 1,412 (54.8) 90 (40.5) 109 (42.2)
0-25 578 (22.0) 46 (20.7) 60 (23.3)
>25 511 (19.5) 72 (32.4) 78 (30.2)
NOTE: Subtypes are defined by the TNP and Core Basal method.
Abbreviation: LVI, lymphovascular invasion.
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associated with younger patient age, lower rates of lympho-
vascular invasion, and with the lowest percentage of positive
axillary lymph node involvement. However, the two schemes
do differ, with an even larger fraction of Core Basal cases being
high grade (87% grade 3), and <40 years old (18.8%) versus
64.4% of 5NP cases that were grade 3, and 10.2% <40 years.
This suggests that the Core Basal classification is identifying a
subset of particularly high-risk patients.
Breast cancer–specific survival by immunohistochemical sub-
type. The breast cancer subtypes as defined by the surrogate
immunopanels differ significantly in predicting breast cancer–
specific survival (Fig. 1). The HER2+/ER-PR- subtype has the
worst breast cancer survival among the four subtypes.
Comparing the survival probabilities between basal-like defi-
nitions, the 10-year breast cancer–specific survival for TNP is
67% [95% confidence interval (95% CI), 63-70; Fig. 1A], but
when the basal-like subtype is segregated into Core Basal and
5NP by adding EGFR and CK5/6 immunostaining information,
the Core Basal group has significantly worse outcome, with an
absolute 10% lower 10-year BCSS than 5NP (Fig. 1B).
The breast cancer subtypes maintain significant independent
prognostic value to predict breast cancer death in the Cox
model, including the established prognostic factors (Table 3).
Compared with luminal¶, which represents the most common
subtype of breast cancers, TNP has a hazard ratio of 1.39 (95%
C.I. 1.17-1.66) for breast cancer–specific death. On the other
hand, the Core Basal group has 1.62 times greater risk for breast
cancer–specific death (95% CI, 1.31-2.00), whereas the 5NP
group does not have statistically or clinically significant
prognostic value (HR, 1.16; 95% CI, 0.91-1.49; Table 3).
The likelihood ratio test between the two Cox models is
significant (P = 0.0273; Table 3).
Because the hazard ratio between luminal¶ and 5NP is not
proportional across time, Cox regression analysis may overes-
timate or underestimate this significance. We ran multivariate
analyses in these TNP tumors to test the significance of Core
Basal association with outcome in this subset. Relative to 5NP,
Core Basal has an estimated hazard ratio of 1.47 (95% CI, 1.08-
1.99) for breast cancer death (Table 4A). The likelihood ratio
test is also significant. Therefore, in this cohort, relying on the
three-biomarker classifier (ER, PR, and HER2) to define basal-
like tumors loses significant information to predict breast
cancer outcome, compared with the five-marker panel incor-
porating EGFR and CK5/6.
Prognostic values of breast cancer subtypes within treatment
subsets. Among the Core Basal patients, 179 received no
adjuvant systemic therapy, 48 were treated with anthracycline-
based chemotherapy (32 with doxorubicin/cyclophosphamide
and 16 with fluorouracil/doxorubicin/cyclophosphamide), and
55 were treated with nonanthracycline-based chemotherapy
(cyclophosphamide, methotrexate, and fluorouracil). Among
the 5NP patients, 141 received no adjuvant systemic therapy,
58 received anthracycline-based chemotherapy (36 doxorubi-
cin/cyclophosphamide and 22 fluorouracil/doxorubicin/cyclo-
phosphamide), and 31 received nonanthracycline-based
chemotherapy. In the no adjuvant systemic therapy subset,
although Core Basal and 5NP were ER-negative, predominantly
grade 3 tumors, most had neither nodal involvement nor
lymphovascular invasion and half were <2 cm (Supplementary
Table S2).
The Core Basal patients who received no adjuvant systemic
therapy (predominantly considered clinically low risk at the
time) have 9% lower 10-year BCSS than similarly treated 5NP
patients (Supplementary Fig. S1A).
Table 2. Clinicopathologic characteristics of the 4,046 breast cancer tumors (Cont’d)
TNP method Core Basal method
Basal (TNP) Basal (Core Basal) 5NP Unassigned
Total n = 639 Total n = 336 Total n =303 Total n = 302
n (% within subtype) n (% within subtype) n (% within subtype) n (% within subtype)
115 (18.0) 71 (21.1) 44 (14.5) 23 (7.6)
149 (23.3) 79 (23.5) 70 (23.1) 48 (15.9)
209 (32.7) 109 (32.4) 100 (33.0) 115 (38.1)
166 (26.0) 77 (22.9) 89 (29.4) 116 (38.4)
n (% within subtype) n (% within subtype) n (% within subtype) n (% within subtype)
12 (1.9) 1 (.3) 11 (3.6) 19 (6.3)
115 (18) 35 (10.4) 80 (26.4) 114 (37.7)
488 (76.4) 293 (87.2) 195 (64.4) 148 (49)
24 (3.8) 7 (2.1) 17 (5.6) 21 (7)
n (% within subtype) n (% within subtype) n (% within subtype) n (% within subtype)
284 (44.4) 152 (45.2) 132 (43.6) 159 (52.6)
300 (46.9) 155 (46.1) 145 (47.9) 111 (36.8)
53 (8.3) 28 (8.3) 25 (8.3) 27 (8.9)
2 (0.3) 1 (.3) 1 (.3) 5 (1.7)
n (% within subtype) n (% within subtype) n (% within subtype) n (% within subtype)
259 (40.5) 135 (40.1) 124 (40.9) 121 (40.1)
351 (54.9) 185 (55.1) 166 (54.8) 166 (55)
29 (4.5) 16 (4.8) 13 (4.3) 15 (5)
n (% within subtype) n (% within subtype) n (% within subtype) n (% within subtype)
378 (59.2) 204 (60.7) 174 (57.4) 172 (57.0)
127 (19.9) 66 (19.6) 61 (20.1) 65 (21.5)
112 (17.5) 55 (16.4) 57 (18.8) 52 (17.2)
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For patients treated with anthracycline-based adjuvant
chemotherapy (Fig. 2), the Core Basal patients have a
significant 26% lower 10-year BCSS than equivalently treated
5NP patients (log-rank P = 1.64  10-3). After adjusting for age,
tumor size, grade, axillary node, and lymphovascular invasion
status, the Core Basal group has a significantly worse survival,
with a hazard ratio of 4.26 versus the 5NP cohort (95% CI,
2.00-9.08; Table 4B). In this patient group, Core Basal status is
the most significant prognosticator in the multivariable model,
ahead of nodal involvement and tumor size. The likelihood
ratio test is significant (P = 7.41  10-5).
On the other hand, among tumors receiving nonanthracy-
cline-based chemotherapy (Supplementary Fig. S1B), outcomes
were relatively poor with no statistically significant survival
difference between Core Basal and 5NP. The tumor character-
istics between nonanthracycline (cyclophosphamide, metho-
trexate, and fluorouracil) versus anthracycline (doxorubicin/
cyclophosphamide or fluorouracil/doxorubicin/cyclophospha-
mide) treated cohorts were similar (Supplementary Table S2);
tumors treated with anthracyclines were mostly diagnosed
between 1990 and 1992.
Discussion
Using a large regional population-based cohort, this study
compared two previously established immunohistochemical
surrogate panels that define breast cancer subtypes. Prognostic
implications of breast cancer molecular subtypes have been
described in several reports (1, 3, 8–10); however, to date, no
studies have been this large (>3700 patients) nor have assessed
breast cancer–specific survival, stratified by adjuvant treatment,
using the triple-negative versus five-biomarker Core Basal
methods. The molecular subtyping of breast cancer is validated
and shown to be an independent prognostic factor. We show
that including positive markers (EGFR and cytokeratins 5/6) for
the basal subtype results in a significantly better identification
of a high-risk group, whose outcome more closely matches that
expected by gene expression profiling (1–3, 5) than was
achieved using a triple-negative (ER-PR-HER2-) definition. Our
results from the multivariable Cox regression analyses strongly
suggest that among the triple-negative cases, the poor prognosis
is conferred almost entirely by the subset of tumors that are
positive for EGFR or basal cytokeratins.
Basal-like breast cancer has been suggested to be definable
by negative ER, PR, and HER2 immunostaining (8, 28–30),
a TNP that can often be extracted from existing clinical
records; however, this definition has never been validated
with microarray data. Our results provide evidence that this
definition can easily be improved upon through the use of
other immunostains already commonly used in surgical
pathology laboratories. The prevalence of the TNP (17%)
in our study is consistent with a recent report that assigned
281 of 1,726 cases (16.3%) as TNP (31). This study found
that among TNP cases, a basal phenotype (defined using
Fig. 1. A, univariable breast cancer ^ specific survival analysis of breast cancer subtypes defined by theTNP method using an immunohistochemical surrogate of HER2, ER,
and PR.The log-rank P value between luminal/HER2+ and luminal¶ is 3.86  10-10; between HER2+/ER-PR- and luminal¶, 1.94  10-17; and between luminal/HER2+ and
HER2+/ER-PR-, 0.159. B, univariable breast cancer ^ specific survival analysis of breast cancer subtypes defined by the Core Basal method using an immunohistochemical
surrogate of HER2, ER, PR, EGFR, and CK5/6. Core Basal has a statistically significant worse survival than 5NP (log-rank P = 8.58  10-3); Core Basal also has a similar
survival rate as HER2+/ER-PR- group for the first 3 y (log-rank P = 0.087).
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CK5/6 and CK14) in a concurrent report (32) by the same
group was significantly prognostic within the node-negative
subset, and further suggested that triple-negative and basal
definitions are associated with good response to chemother-
apy (although treatments were not randomized and infor-
mation on chemotherapy regimens was not given). The
specific Core Basal definition used here and based on
previous independent series was not presented and therefore
direct comparisons are difficult to make. Another study, using
375 stage II breast tumors treated with tamoxifen but not
adjuvant chemotherapy, defined 48 tumors as basal-like on
the basis of cytokeratin 5 or 14 immunostaining, and
reported no significant survival differences among ER-
negative tumors (33). The discrepancy is likely due to
limited power and the different choice of surrogate bio-
markers, as cytokeratin 14 has not been found by gene
expression to be a marker for basal-like tumors. In our ‘‘pure
prognostic’’ group of patients receiving no adjuvant systemic
therapy, Core Basal (10-year BCSS 70%) and HER2+/ER-
PR- (10-year BCSS 59%) subtypes are associated with
significantly distinct breast cancer–specific survival in uni-
variable Kaplan-Meier analysis (log-rank P = 0.0395), with an
adjusted hazard ratio of 0.74 (95% CI, 0.438-1.04). Our
results support that basal-like phenotype breast tumors,
having a different natural history than HER2+/ER-PR-, display
a clinically distinct outcome, as well as distinct clinical
features such as high grade, node-negative progression, and
higher prevalence in young patients.
By adding EGFR and CK5/6 as positive markers, a signifi-
cantly worse outcome group can be identified among triple-
negative cases. The Core Basal definition is associated with even
poorer breast cancer survival in the whole population-based
cohort, and also in the anthracycline-based chemotherapy
cohort, a generally high-risk group treated with similar
regimens in contemporary practice. Poor outcome despite
anthracycline treatment is concordant with a recent case-
control study (47 basal cytokeratin-expressing breast cancers
and 49 stage-matched but mainly ER+ controls; ref. 34). Other
studies (8, 14, 35) have reported that the basal-like subtype is a
potential candidate to respond well to chemotherapy. In a
neoadjuvant study, basal-like tumors (defined by TNP) had
higher rates (27%) of pathologic complete response to
anthracycline-based neoadjuvant chemotherapy than luminal
breast cancers (36). However, those triple-negative tumors,
which did not have complete response, had the highest rate of
relapse, potentially explaining the poor prognosis of basal-like
tumors as a group despite aggressive chemotherapy. Our
findings are compatible with a recent study done analyzing
823 patients from two clinical trials randomized to receive
anthracyclines versus no adjuvant chemotherapy (37). In that
study, a ‘‘true basal’’ group defined as HER2 negative, ER
negative, and either EGFR or CK5/6 positive exhibited less
benefit from anthracyclines than the group negative for all four
of these markers.
One limitation of our study is that our cohort derives from
a regional population base. Adjuvant! is a computer software
program that predicts breast cancer outcomes based on
Surveillance, Epidemiology, and End-Results data and clinical
trial meta-analyses to guide treatment decisions in clinical
practice (38). Almost half of our data set was used in an earlier
study confirming that, in the British Columbia population,
Adjuvant! predictions are comparable with observed outcomes
(16), supporting extrapolation of the conclusions drawn in the
present study to North American populations.
Table 3. Cox regression analysis to estimate the adjusted hazard ratios of breast cancer subtypes defined by
TNP and Core Basal method, respectively, on 3,558 cases with sufficient information for all of the variables
Variables Univariate analysis Multivariate analysis
HR (95% CI) Nested Cox model HR (95% CI) Full Cox model HR (95% CI)
Age, y
40-49 vs V40 0.62 (0.51-0.76) 0.73 (0.59-0.91) 0.74 (0.59-0.92)
50-65 vs V40 0.65 (0.54-0.78) 0.83 (0.68-1.01) 0.84 (0.69-1.02)
>65 vs V40 0.65 (0.54-0.78) 0.87 (0.71-1.07) 0.89 (0.72-1.09)
Grade
3 vs (2 and 1) 2.11 (1.86-2.39) 1.49 (1.30-1.71) 1.47 (1.28-1.69)
Lymphovascular invasion
Positive vs negative 2.28 (2.02-2.58) 1.31 (1.13-1.53) 1.32 (1.14-1.53)
Tumor size, cm
2-5 vs V2 2.08 (1.84-2.36) 1.65 (1.44-1.88) 1.65 (1.44-1.88)
>5 vs V2 3.32 (2.69-4.09) 1.77 (1.38-2.27) 1.77 (1.39-2.27)
Percentage of positive/dissected axillary lymph nodes
0-25 vs 0 1.98 (1.70-2.31) 1.62 (1.36-1.92) 1.62 (1.37-1.93)
>25 vs 0 3.99 (3.48-4.58) 2.88 (2.44-3.40) 2.89 (2.45-3.42)
Breast cancer subtype
Luminal¶ as reference
Luminal/HER2+ 1.93 (1.55-2.40) 1.41 (1.11-1.79) 1.41 (1.12-1.79)
HER2+/ER-PR- 2.27 (1.86-2.76) 1.88 (1.52-2.33) 1.89 (1.53-2.34)
Unassigned 1.02 (0.81-1.29) 1.12 (0.87-1.44) 1.13 (0.99-1.45)
TNP 1.50 (1.28-1.74) 1.39 (1.17-1.66)
Core Basal 1.77 (1.46-2.14) 1.62 (1.31-2.00)
5NP 1.22 (0.97-1.52) 1.16 (0.91-1.49)
NOTE: Hazard ratios above 1.0 indicate poorer outcome. Likelihood ratio test of TNP (nested model) and Core Basal (full model) methods has a
P value of 0.0273. Hazard ratios for individual clinicopathologic variables in univariable breast cancer–specific survival listed for reference.
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In British Columbia, most patients were treated according
to provincial guidelines developed and disseminated by the
British Columbia Cancer Agency. Associations relying on
nonrandomized treatment regimens (such as the apparent
poor outcomes of Core Basal over 5NP tumors in the
adjuvant anthracycline subset) are best considered hypothesis
generating. Thus, our finding that the Core Basal definition
may predict response of anthracycline-based adjuvant chemo-
therapies needs validation. Prospective clinical trial designs
are clearly needed to investigate the benefit of different
chemotherapy regimens in basal-like breast cancer. Use of a
triple-negative definition is attractive in the design of such
studies as it does not necessitate additional biomarker
information. However, a major implication of our current
study is that relying on a TNP definition of basal-like breast
cancer will still identify a heterogeneous group with
significant differences in survival, potentially obscuring
important findings.
In North American and European populations, f12% to
20% of breast cancer patients have basal-like gene expression
profiles and/or a triple-negative immunophenotype (1, 3, 30,
31). Our results provide strong evidence to support the use of a
five-biomarker surrogate (ER, PR, HER2, EGFR, and CK5/6) to
define the basal-like subtype, a finding of immediate relevance
to prognostication and clinical trial design. Drawing on readily
available inexpensive diagnostic tools already in clinical use,
this immunopanel provides a more specific definition of this
aggressive form of breast cancer for which there is a particular
need to improve therapeutic options.
Table 4. Cox regression analyses on basal (TNP)
tumors
A. Cox regression analysis on 575 basal (TNP) tumors with
sufficient information for the clinicopathologic covariates:
age, tumor size, grade, lymphovascular invasion, and
percentage positive among total examined axillary lymph
nodes. Likelihood ratio test, P = 0.0127, df = 1
Variables Hazard ratio (95% CI)
Age, y
40-49 vs V40 1.13 (0.74-1.74)
50-65 vs V40 1.01 (0.67-1.53)
>65 vs V40 1.11 (0.71-1.74)
Grade
3 vs (2 and 1) 1.31 (0.86-1.97)
Lymphovascular invasion
Positive vs negative 1.72 (1.21-2.44)
Tumor size, cm
2-5 vs V2 1.68 (1.22-2.32)
>5 vs V2 1.72 (1.04-2.84)
Percentage of
positive/total number
of dissected axillary
lymph nodes
0-25 vs 0 1.57 (1.07-2.30)
>25 vs 0 2.64 (1.77-3.96)
Breast cancer subtype
Basal (Core Basal) vs 5NP 1.47 (1.08-1.99)
Fig. 2. Univariablebreast cancer ^ specific analysis among106TNP tumors
receivinganthracycline-basedadjuvantchemotherapy regimen.Solidline,CoreBasal
cases expressingEGFRorCK5/6.Dashed line, 5NPcases expressingnoneof
thesemarkers.
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